AUTHOR=Raturi Vijay P. , Tochinai Taku , Hojo Hidehiro , Rachi Toshiya , Hotta Kenji , Nakamura Naoki , Zenda Sadamoto , Motegi Atsushi , Ariji Takaki , Hirano Yasuhiro , Baba Hiromi , Ohyoshi Hajime , Nakamura Masaki , Okumura Masayuki , Bei Yanping , Akimoto Tetsuo 

TITLE=Dose–Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis

JOURNAL=Frontiers in Oncology

VOLUME=10

YEAR=2020

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.517061

DOI=10.3389/fonc.2020.517061

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> Radiobiological model-based studies of photon-modulated radiotherapy for pancreatic cancer have reported reduced gastrointestinal (GI) toxicity, although the risk is still high. The purpose of this study was to investigate the potential of 3D-passive scattering proton beam therapy (3D-PSPBT) in limiting GI organ at risk (OAR) toxicity in localized pancreatic cancer based on dosimetric data and the normal tissue complication probability (NTCP) model.</p><p><bold>Methods:</bold> The data of 24 pancreatic cancer patients were retrospectively analyzed, and these patients were planned with intensity-modulated radiotherapy (IMRT), volume-modulated arc therapy (VMAT), and 3D-PSPBT. The tumor was targeted without elective nodal coverage. All generated plans consisted of a 50.4-GyE (Gray equivalent) dose in 28 fractions with equivalent OAR constraints, and they were normalized to cover 50% of the planning treatment volume (PTV) with 100% of the prescription dose. Physical dose distributions were evaluated. GI-OAR toxicity risk for different endpoints was estimated by using published NTCP Lyman–Kutcher–Burman (LKB) models. Analysis of variance (ANOVA) was performed to compare the dosimetric data, and ΔNTCP<sub>IMRT−PSPBT</sub> and ΔNTCP<sub>VMAT−PSPBT</sub> were also computed.</p><p><bold>Results:</bold> Similar homogeneity and conformity for the clinical target volume (CTV) and PTV were exhibited by all three planning techniques (<italic>P</italic> &gt; 0.05). 3D-PSPBT resulted in a significant dose reduction for GI-OARs in both the low-intermediate dose range (below 30 GyE) and the highest dose region (<italic>D</italic><sub>max</sub> and <italic>V</italic><sub>50 GyE</sub>) in comparison with IMRT and VMAT (<italic>P</italic> &lt; 0.05). Based on the NTCP evaluation, the NTCP reduction for GI-OARs by 3D-PSPBT was minimal in comparison with IMRT and VMAT.</p><p><bold>Conclusion:</bold> 3D-PSPBT results in minimal NTCP reduction and has less potential to substantially reduce the toxicity risk of upper GI bleeding, ulceration, obstruction, and perforation endpoints compared to IMRT and VMAT. 3D-PSPBT may have the potential to reduce acute dose-limiting toxicity in the form of nausea, vomiting, and diarrhea by reducing the GI-OAR treated volume in the low-to-intermediate dose range. However, this result needs to be further evaluated in future clinical studies.</p>